Dec 19, 2022
Aravax commences Phase 2 in peanut allergy with $20m Series B from Brandon Capital and Tenmile
20 December 2022, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company developing the first safe, convenient, and...
top of page
Developing safe, convenient, disease-modifying treatments for food allergies.
.jpg)
News
bottom of page